Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRPR | P30550 | 6/20 | 0.57 |
| ▸ | REN | P00797 | 5/20 | 0.53 |
| ▸ | NPBWR1 | P48145 | 3/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31494985 | 0.95 | REN (0.53) | GRPRRENNPBWR1OPRM1OPRD1 | |
| SCHEMBL29473430 | 0.95 | REN (0.55) | GRPRRENNPBWR1OPRM1OPRD1 | |
| SCHEMBL16716014 | 0.94 | GRPR (0.57) | GRPRREN | |
| SCHEMBL12767725 | 0.94 | GRPR (0.58) | GRPRRENNPBWR1 | |
| SCHEMBL30398505 | 0.94 | GRPR (0.64) | GRPR | |
| SCHEMBL30118088 | 0.94 | GRPR (0.62) | GRPRREN | |
| SCHEMBL29484960 | 0.92 | GRPR (0.67) | GRPR | |
| SCHEMBL29484954 | 0.92 | GRPR (0.67) | GRPR | |
| SCHEMBL38660507 | 0.89 | GRPR (0.58) | GRPRNPBWR1OPRM1OPRD1 | |
| SCHEMBL31494987 | 0.89 | GRPR (0.56) | GRPRNPBWR1OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12269837-B2 | Bifunctional do2pa derivatives, chelates with metallic cations and use thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2025-04-08 | — | — | US | disclosed |
| EP-4188457-A1 | CONJUGATE OR ITS SALT COMPRISING A GASTRIN-RELEASING PEPTIDE RECEPTOR ANTAGONIST AND USES THEREOF | Orano Med (FR) | 2023-06-07 | — | — | EP | disclosed |
| EP-4076541-A1 | MODIFIED GRPR ANTAGONIST PEPTIDES FOR IMAGING AND THERAPY OF CANCER | Technische Universität München (DE) | 2022-10-26 | — | — | EP | disclosed |
| US-20220143230-A1 | BIFUNCTIONAL do2pa DERIVATIVES, CHELATES WITH METALLIC CATIONS AND USE THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2022-05-12 | — | — | US | disclosed |
| WO-2022063850-A1 | CONJUGATE OR ITS SALT COMPRISING A GASTRIN-RELEASING PEPTIDE RECEPTOR ANTAGONIST AND USES THEREOF | ORANO MED (FR) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220143230-A1 | BIFUNCTIONAL do2pa DERIVATIVES, CHELATES WITH METALLIC CATIONS AND USE THEREOF | AP2A2, ATP2A2, SLC20A2 | GRPR 2119/4885REN 3185/4885NPBWR1 2045/4885 |
| US-12269837-B2 | Bifunctional do2pa derivatives, chelates with metallic cations and use thereof | AP2A2, ATP2A2, SLC20A2 | GRPR 2119/4885REN 3185/4885NPBWR1 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.